Search the Newsreel

enVVeno Study Projects About 2.2 Fewer Venous Ulcers Per Patient

A recently published health economic study in the Journal of Vascular Surgery found enVVeno Medical's VenoValve to be economically dominant over standard care for severe deep venous reflux. The analysis projected over $32,000 in average healthcare savings and approximately 2.2 fewer venous ulcers per …

enVVe Venous Valve Trial Expected to Enroll About 230 Patients

enVVeno Medical (NASDAQ: NVNO) received FDA IDE approval for its TAVVE pivotal trial, which will evaluate the enVVe minimally invasive replacement venous valve for severe deep chronic venous insufficiency. The trial is expected to enroll approximately 230 patients across up to 40 U.S. sites, …

enVVeno Medical Reports Second Quarter 2026 Financial Results and Advances Towards FDA Pivotal Trial for First-in-Class Non-Surgical Replacement Venous Valve

enVVeno Medical reported its second-quarter 2026 financial results, highlighted by receiving FDA IDE approval for the TAVVE pivotal trial for its enVVe® System, a non-surgical venous valve replacement. The company plans to begin enrolling patients for the trial in the second half of 2026, …

FDA IDE pivotal trial and 2027 cash runway for enVVeno Medical (NASDAQ: NVNO)

enVVeno Medical (NVNO) has received FDA Investigational Device Exemption (IDE) approval for its TAVVE pivotal study of the enVVe System, a transcatheter venous valve for severe Chronic Venous Insufficiency. The company reported a reduced net loss of $3.6 million in Q2 2026, down from …

enVVeno Medical Corporation Revenue Breakdown – LS:A42085

This article provides a financial overview of enVVeno Medical Corporation (LS:A42085) with a focus on its revenue breakdown, though specific figures are not directly presented in the provided text. It covers essential financial data, including statements, statistics, dividends, earnings, and segment reports. The content …

NVNO|enVVeno Medical Corp|Price:10.320|Chg%:-0.070

This article provides a comprehensive stock analysis of enVVeno Medical Corp (NVNO), highlighting its weak fundamentals, high growth potential, and fair valuation within the Biotechnology & Medical Research industry. Despite high institutional ownership and a "Strong Buy" analyst rating with a target price of …

enVVeno Medical Corp (NVNO) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of enVVeno Medical Corp (NVNO), listing major individual and institutional holders, their proportional ownership, and recent changes in holdings. It also breaks down shareholder types, including individual investors, investment advisors, and hedge funds, and provides institutional shareholding trends …

NVNO Q3 2025 Earnings: Narrower Loss Surprises as Company Advances Venous Therapy Pipeline - Banking Earnings Report

enVVeno Medical Updates Investors With New Presentation

enVVeno Medical (NVNO) has released a new investor presentation through a Form 8-K filing, aimed at updating investors, analysts, and other stakeholders on the company’s business, strategy, clinical progress, and market opportunities. While a recent analyst rating suggests a "Buy" with a $30.00 price …

enVVeno's non-surgical valve trial gets first-ever FDA IDE approval

enVVeno Medical (NASDAQ: NVNO) releases updated investor presentation

enVVeno Medical Secures Transformational U.S. Patent for enVVe System, Strengthening Competitive Moat Ahead of Launch of Historic FDA Pivotal Trial

NVNO Q3 2025 Earnings: Narrower-than-Expected Loss Drives Positive Stock Reaction - Downward Estimate Revision

Should I buy enVVeno Medical (NVNO)

Envveno Medical Corporation (NVNO) Stock Price, News & Analysis

enVVeno Medical Corporation (NVNO) stock price, news, quote and history

enVVeno Medical Corporation (NVNO) Income Statement

enVVeno Medical (NVNO) Earnings Date and Reports 2026

enVVeno Medical (NVNO) Stock Price, News & Analysis